Evaluation of Different Commercial Sealing Hemostatic Patches for Their Selection as Reservoirs for Localized Intraperitoneal Chemotherapy

Sep 30, 2026

Upload by Jiven

Peritoneal carcinomatosis is typically managed with cytoreductive surgery followed by chemotherapy, where sealing hemostatic patches help prevent uncontrolled bleeding. These patches, often based on oxidized cellulose or collagen with a binding agent, may also function as drug delivery systems when the attached tissue is used as a reservoir for localized intraperitoneal chemotherapy. The study characterizes three commercial patches, compares key properties, and selects Hemopatch as the most suitable. Using Hemopatch as a scaffold, a hyaluronic acid hydrogel loaded with cisplatin or olaparib enables sustained release for over 6 days while preserving anticancer efficacy on OVCAR-3 cells. The results support integrating a drug delivery system into hemostatic patches to target residual microscopic disease after surgery.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages11

Reading Time28 min

AccessFree to download

Abstract

Keywords

This article is licensed under CC-BY 4.0 [pubs.acs.org/ptsci](pubs.acs.org/ptsci) Article Evaluation of Different Commercial Sealing Hemostatic Patches for Their Selection as Reservoirs for Localized Intraperitoneal Chemotherapy M. Teresa Perelló-Trias,¶ Ana Rodríguez-Fernández,¶ Antonio Jose Serrano-Mũnoz, Juan J. Segura-Sampedro, Pedro Tauler, Joana M. Ramis, * and Marta Monjo * Cite This: ACS Pharmacol. Transl. Sci. 2025, 8, 499−509 Read Online | | | | | | | | --- | --- | --- | --- | --- | --- | | ACCESS | Metrics & More | | Article Recommendations | | *sı Supporting Information | ABSTRACT: Peritoneal carcinomatosis (PC) is typically treated by cytoreductive surgery (CRS) and subsequent chemotherapy. Sealing hemostatic patches (HP) are often used during these surgeries to prevent complications such as uncontrolled bleeding. These HP are made of biomaterials like oxidized cellulose or collagen with a binding agent, and beyond their usual function, they could also be used as drug delivery systems (DDS) for localized intraperitoneal chemotherapy in the tissue attached. Our first aim was to characterize and compare three different commercial HP (TachoSil®, Hemopatch®, and VerisetTM). Hemopatch® emerged as the most suitable candidate due to its combination of properties, including slow degradation, high hydrophilicity, excellent biological fluid absorption capacity, and moderate adhesive capacity alongside hemostasis. Utilizing Hemopatch® as a scaffold, we developed a new device incorporating a hyaluronic acid hydrogel loaded with cisplatin or olaparib. This approach facilitated sustained drug release for over 6 days, maintaining the anticancer efficacy of these agents on OVCAR-3 cells. In conclusion, integrating a DDS into HP shows potential for precisely delivering chemotherapeutic agents to any residual microscopic disease in PC following CRS. KEYWORDS: hemostatic patch, drug delivery system, hydrogel, hyaluronic acid, localized intraperitoneal chemotherapy Cancer is currently one of the most prevalent diseases worldwide, and it stands as the second leading cause of death after cardiovascular diseases.1,2 Cancer originating from organs in the peritoneal cavity, such as the stomach, colon, liver, and ovary, can spread along the peritoneum, which is a condition known as peritoneal carcinomatosis (PC). This poses a significant challenge in managing the disease and is usually associated with decreased overall survival and poor prognosis.3 Current treatment for peritoneal malignancies involves cytoreductive surgery (CRS), followed by chemotherapy to remove microscopic residues. CRS aims to remove as much tumor tissue as possible. Still, it is also the first way to control the dissemination of metastatic cells in the peritoneal cavity. The remnant of cancer cells at the surgical resection margin appears to be a significant trigger for recurrences. Also, intraoperative bleeding due to tissue damage during tumor resection can be a critical factor in the dissemination of tumor cells into the blood and surrounding area, increasing the risk of new metastatic foci.4,5 Thus, adequate bleeding management during CRS is essential for intraoperative and postoperative complications as it can reducedrain placement and hospitalization time, morbidity, mortality, postsurgery costs, and metastasis events.6−8 Techniques such as electrocautery, compression, or ligatures are commonly used | Received: October 18, 2024
Revised: December 5, 2024
Accepted: December 17, 2024
Published: January 8, 2025 | | | --- | --- | © 2025 The Authors. Published by American Chemical Society 499 [https://doi.org/10.1021/acsptsci.4c00608](https://doi.org/10.1021/acsptsci.4c00608)[ ](https://doi.org/10.1021/acsptsci.4c00608)[ACS Pharmacol](ACS Pharmacol). Transl. Sci. 2025, 8, 499−509 Figure 1. Graphical composition of three commercial hemostatic patches (TachoSil®, Hemopatch®, and VerisetTM) evaluated and character

FAQs

What clinical problem does the study target in peritoneal carcinomatosis treatment?

It targets uncontrolled bleeding during cytoreductive surgery, while also aiming to use sealing hemostatic patches as reservoirs for localized intraperitoneal chemotherapy to treat residual microscopic disease.

Which three commercial sealing hemostatic patches were evaluated?

TachoSil®, Hemopatch®, and VerisetTM were characterized and compared for their suitability as drug-delivery reservoirs.

How was the Hemopatch-based device designed and what did it achieve?

The researchers used Hemopatch as a scaffold to develop a hyaluronic acid hydrogel loaded with cisplatin or olaparib, enabling sustained drug release for over 6 days and maintaining anticancer efficacy on OVCAR-3 cells.

Sep 30, 2026

Upload by Jiven